ETFs

ETF News

20 stories
thenewswire

Juggernaut Receives $10,341,500 from Warrants Exercised

(TheNewswire)Vancouver, British Columbia – TheNewswire - June 29, 2026 – Juggernaut Exploration Ltd (JUGR.V) (OTCPK: JUGRF) (FSE: 4JE) (the “Company” or “Juggernaut”) is pleased to announce it has received $10,341,500 from a 100% exercise of its $0.75 warrants previously announced on May 26, 2026…

TheNewswire en
ETFsStocksCA

REG - European Green Trns. - Results of Annual General Meeting

RNS Number : 2046K European Green Transition PLC 29 June 2026  European Green Transition PLC("EGT", or the "Company")Results of Annual General Meeting29 June 2026 - European Green Transition plc (AIM: EGT), a company operating in the critical infrastructure sector, confirms that all resolutions…

London Stock Exchange en
ETFsStocksGB
NEWS eqs

Embera Partners GmbH: A New Category for European Capital Market

Issuer: Embera Partners GmbH/ Key word(s): MiscellaneousEmbera Partners GmbH: A New Category for European Capital Market29.06.2026 / 13:20 CET/CESTThe issuer is solely responsible for the content of this announcement.A New Category for European Capital MarketIntroducing ECI Capital Markets Intellig…

EQS en
ETFs

REG - Cirata PLC - Result of Retail Offer

RNS Number : 2041K Cirata PLC 29 June 2026  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION…

London Stock Exchange en
ETFsStocksGB
NEWS zawya

ZAWYA: GCC asset management reaches $2.7trln in 2025, up 10% from 2024

Riyadh, KSA – Assets under management (AuM[1]) in the GCC grew by 10% in 2025, reaching $2.7 trillion and marking one of the strongest annual performances in over a decade, according to a new report from Boston Consulting Group (BCG). The findings, released as part of BCG's Global Asset Management…

Zawya en
EconomyETFs
prnewswire

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"…

PR Newswire en
ETFsStocksUS
NEWS prnewswire

Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases

Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined company at closing anticipated to fund TALA-125 through a Phase 2b proof-of-concept study data readout in the second half of 2028Talawar, the first company formed to develop and c…

PR Newswire en
ETFsStocksUS
dow-jones

Prosus Beats Expectations, Partly on Latin America Strength — Market Talk

Tech investor Prosus beat expectations for fiscal 2026, with a positive performance in Latin America helping its results, ING's Marc Hesselink says in a research note. Revenue exceeded consensus expectations by 7%, due to a strong performance from its iFood food-delivery unit in Latin America despi…

Dow Jones Newswires en
ETFsStocksNL

The 10-Point: The Wall Street Journal's Guide to the Day's Top News

By Emma TuckerThis morning, we bring you the story of how a master of deception conned investors out of $50 million — in his own words. Paul Regan recorded himself ripping off investors, offering rare access into the inner workings of a fraud. Federal prosecutors say Regan and his co-conspirators m…

Dow Jones Newswires en
ETFsindexStocksUS
globenewswire

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

BALA CYNWYD, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) NASDAQ:LRMR, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced it has submitted the first module of its rolling Biologics License Application (BL…

GlobeNewswire en
ETFsStocksUS